IPO Pricing In the previous two questions, how would it affect your thinking to know that in addition to the 6.5 million shares offered in the IPO, Eyetech had an additional 32 million shares outstanding? Of the 32 million shares, 10 million shares were owned by pharmaceutical giant Pfizer, and 12 million shares were owned by the 13 directors and executive officers.

 LO.1